ESR1 and breast carcinoma: Therefore, immune scores may not only be used as prognostic biomarker for breast cancer patients, but also have potential clinical values in the choice of therapeutic strategies.22, 24 Importantly, we found that patients with higher immune scores tended to be ER, PR, and HER2 negative.